Literature DB >> 12757975

Telomere-driven genomic instability in cancer cells.

Chantal Desmaze1, Jean-Charles Soria, Marie-Anne Freulet-Marrière, Noelle Mathieu, Laure Sabatier.   

Abstract

Telomeres, the ends of linear chromosomes, play a major role in the maintenance of genome integrity. Telomerase or alternative lengthening of telomeres (ALT) mechanisms exist in most cancer cells in order to stabilize telomere length by the addition of telomeric repeats. Telomere loss can be dramatically mutagenic. Chromosomes lacking one telomere remain unstable until they are capped, generating chromosomal instability, gene amplification via breakage/fusion/bridge (B/F/B) cycles and resulting in chromosome imbalances. The chronology of the occurrence of gene amplification and chromosome imbalances detected in human tumors is still unknown. All of the aberrations that occur prior to, during or after activation of a telomere maintenance mechanism promote the development of cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12757975     DOI: 10.1016/s0304-3835(02)00704-8

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  19 in total

1.  The labeling efficiency of human telomeres is increased by double-strand PRINS.

Authors:  Ju Yan; Bing-Zhen Chen; Eric F Bouchard; Régen Drouin
Journal:  Chromosoma       Date:  2004-09-02       Impact factor: 4.316

2.  The relationship between telomere length and clinicopathologic characteristics in colorectal cancers among Tunisian patients.

Authors:  Raja Mzahma; Maher Kharrat; Fadhel Fetiriche; Mounir Ben Moussa; Zoubeir Ben Safta; Chadli Dziri; AbdelJelil Zaouche; Habiba Chaabouni-Bouhamed
Journal:  Tumour Biol       Date:  2015-06-06

3.  Chromosome arm-specific long telomeres: a new clonal event in primary chronic myelogenous leukemia cells.

Authors:  Oumar Samassekou; Huiyu Li; Josée Hébert; Aimé Ntwari; Haixia Wang; Catherine Grenier Cliché; Eric Bouchard; Shiang Huang; Ju Yan
Journal:  Neoplasia       Date:  2011-06       Impact factor: 5.715

4.  Alternative lengthening of telomeres: recurrent cytogenetic aberrations and chromosome stability under extreme telomere dysfunction.

Authors:  Despoina Sakellariou; Maria Chiourea; Christina Raftopoulou; Sarantis Gagos
Journal:  Neoplasia       Date:  2013-11       Impact factor: 5.715

5.  Organ-wide telomeric status in diseased and disease-free prostatic tissues.

Authors:  Christopher M Heaphy; Trisha M Fleet; Eric G Treat; Sang-Joon Lee; Anthony Y Smith; Michael S Davis; Jeffrey K Griffith; Edgar G Fischer; Marco Bisoffi
Journal:  Prostate       Date:  2010-09-15       Impact factor: 4.104

6.  Human telomeric DNA sequences are a major target for the antitumour drug bleomycin.

Authors:  Trung V Nguyen; Vincent Murray
Journal:  J Biol Inorg Chem       Date:  2011-07-15       Impact factor: 3.358

7.  Influence of mindfulness-based stress reduction (MBSR) on telomerase activity in women with breast cancer (BC).

Authors:  Cecile A Lengacher; Richard R Reich; Kevin E Kip; Michelle Barta; Sophia Ramesar; Carly L Paterson; Manolete S Moscoso; Irina Carranza; Pinky H Budhrani; Seung Joon Kim; Hyun Y Park; Paul B Jacobsen; Michael J Schell; Heather S L Jim; Janice Post-White; Jerrica R Farias; Jong Y Park
Journal:  Biol Res Nurs       Date:  2014-01-30       Impact factor: 2.522

8.  The DNA sequence specificity of bleomycin cleavage in telomeric sequences in human cells.

Authors:  Hanh T Q Nguyen; Vincent Murray
Journal:  J Biol Inorg Chem       Date:  2012-09-09       Impact factor: 3.358

9.  Three-dimensional telomere dynamics in follicular thyroid cancer.

Authors:  Landon Wark; Adrian Danescu; Suchitra Natarajan; Xuguang Zhu; Sheue-yann Cheng; Sabine Hombach-Klonisch; Sabine Mai; Thomas Klonisch
Journal:  Thyroid       Date:  2013-09-04       Impact factor: 6.568

10.  A role for monoubiquitinated FANCD2 at telomeres in ALT cells.

Authors:  Qiang Fan; Fan Zhang; Briana Barrett; Keqin Ren; Paul R Andreassen
Journal:  Nucleic Acids Res       Date:  2009-01-07       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.